Concepts (188)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myelodysplastic Syndromes | 7 | 2023 | 379 | 1.080 |
Why?
|
| Drug Industry | 1 | 2023 | 56 | 0.760 |
Why?
|
| Registries | 8 | 2023 | 990 | 0.720 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 5 | 2020 | 147 | 0.590 |
Why?
|
| Azacitidine | 2 | 2017 | 149 | 0.530 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 12 | 2025 | 2544 | 0.420 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 9 | 2023 | 939 | 0.350 |
Why?
|
| Topotecan | 2 | 2009 | 46 | 0.350 |
Why?
|
| Prospective Studies | 10 | 2023 | 4560 | 0.300 |
Why?
|
| Blood Coagulation Factor Inhibitors | 1 | 2008 | 4 | 0.290 |
Why?
|
| Blood Coagulation Disorders | 1 | 2008 | 66 | 0.270 |
Why?
|
| Alemtuzumab | 1 | 2025 | 90 | 0.220 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2017 | 244 | 0.220 |
Why?
|
| Aged, 80 and over | 10 | 2025 | 7061 | 0.200 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2023 | 826 | 0.200 |
Why?
|
| Pathology, Molecular | 1 | 2023 | 34 | 0.200 |
Why?
|
| Laboratories | 1 | 2023 | 46 | 0.200 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2025 | 224 | 0.180 |
Why?
|
| Rituximab | 3 | 2020 | 128 | 0.180 |
Why?
|
| Lymphoma, Non-Hodgkin | 4 | 2010 | 260 | 0.170 |
Why?
|
| Aged | 17 | 2025 | 20434 | 0.170 |
Why?
|
| Erythroblasts | 1 | 2020 | 27 | 0.170 |
Why?
|
| RNA Splicing Factors | 1 | 2020 | 30 | 0.160 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2025 | 423 | 0.160 |
Why?
|
| Thrombocytopenia | 2 | 2020 | 189 | 0.160 |
Why?
|
| Humans | 33 | 2025 | 93515 | 0.150 |
Why?
|
| Middle Aged | 22 | 2025 | 27573 | 0.150 |
Why?
|
| Phosphoproteins | 1 | 2020 | 259 | 0.150 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 97 | 0.150 |
Why?
|
| Adult | 22 | 2025 | 27918 | 0.150 |
Why?
|
| Treatment Outcome | 8 | 2025 | 9099 | 0.140 |
Why?
|
| Multiple Myeloma | 1 | 2022 | 338 | 0.140 |
Why?
|
| Cytogenetics | 1 | 2017 | 27 | 0.140 |
Why?
|
| Hematopoietic Stem Cells | 4 | 2009 | 319 | 0.130 |
Why?
|
| Vidarabine | 1 | 2017 | 93 | 0.130 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2017 | 361 | 0.120 |
Why?
|
| Female | 24 | 2025 | 48702 | 0.120 |
Why?
|
| Male | 19 | 2025 | 44557 | 0.120 |
Why?
|
| Antigens, CD34 | 5 | 2009 | 161 | 0.120 |
Why?
|
| Cyclophosphamide | 4 | 2000 | 278 | 0.110 |
Why?
|
| Hematologic Neoplasms | 2 | 2009 | 372 | 0.100 |
Why?
|
| Bone Marrow Transplantation | 3 | 2002 | 281 | 0.100 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 3 | 2010 | 52 | 0.100 |
Why?
|
| Quality of Life | 3 | 2016 | 1780 | 0.090 |
Why?
|
| Leucovorin | 1 | 1992 | 200 | 0.090 |
Why?
|
| Fluorouracil | 2 | 1998 | 524 | 0.090 |
Why?
|
| Young Adult | 6 | 2025 | 6930 | 0.080 |
Why?
|
| United States | 4 | 2020 | 7622 | 0.080 |
Why?
|
| Salvage Therapy | 2 | 2010 | 235 | 0.080 |
Why?
|
| Hodgkin Disease | 2 | 2010 | 145 | 0.080 |
Why?
|
| Thiotepa | 3 | 2000 | 32 | 0.080 |
Why?
|
| Drug Administration Schedule | 2 | 2009 | 829 | 0.080 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2010 | 113 | 0.080 |
Why?
|
| Administration, Oral | 2 | 2009 | 657 | 0.080 |
Why?
|
| Blood Coagulation Tests | 1 | 2008 | 32 | 0.070 |
Why?
|
| Adenocarcinoma | 2 | 1995 | 1173 | 0.070 |
Why?
|
| Breast Neoplasms | 5 | 2001 | 3110 | 0.070 |
Why?
|
| Paclitaxel | 2 | 2001 | 479 | 0.070 |
Why?
|
| Thalidomide | 1 | 2008 | 55 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2025 | 1001 | 0.070 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 3830 | 0.060 |
Why?
|
| Prognosis | 4 | 2017 | 3911 | 0.060 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 4 | 2001 | 158 | 0.060 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2006 | 11 | 0.060 |
Why?
|
| Leukocyte Count | 4 | 2001 | 210 | 0.060 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2006 | 17 | 0.060 |
Why?
|
| Pancreatic Neoplasms | 1 | 1992 | 715 | 0.060 |
Why?
|
| Risk Factors | 2 | 2014 | 5899 | 0.060 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2006 | 68 | 0.060 |
Why?
|
| Leukapheresis | 3 | 2001 | 16 | 0.060 |
Why?
|
| CD52 Antigen | 1 | 2025 | 6 | 0.060 |
Why?
|
| Transplantation Conditioning | 2 | 2009 | 383 | 0.050 |
Why?
|
| Stem Cell Transplantation | 1 | 2006 | 192 | 0.050 |
Why?
|
| Body Weight | 1 | 2006 | 449 | 0.050 |
Why?
|
| Immunologic Factors | 1 | 2006 | 176 | 0.050 |
Why?
|
| Survival Rate | 6 | 2010 | 1948 | 0.050 |
Why?
|
| Patient Compliance | 1 | 2005 | 237 | 0.050 |
Why?
|
| Transplantation, Homologous | 4 | 2009 | 1014 | 0.050 |
Why?
|
| Remission Induction | 3 | 2017 | 738 | 0.050 |
Why?
|
| Immunosuppressive Agents | 1 | 2008 | 990 | 0.050 |
Why?
|
| Imides | 1 | 2022 | 26 | 0.050 |
Why?
|
| Proteasome Inhibitors | 1 | 2022 | 52 | 0.050 |
Why?
|
| Transplantation, Autologous | 4 | 2010 | 359 | 0.040 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2000 | 134 | 0.040 |
Why?
|
| Platelet Count | 2 | 1999 | 90 | 0.040 |
Why?
|
| Combined Modality Therapy | 5 | 2010 | 1723 | 0.040 |
Why?
|
| Neoplasm, Residual | 1 | 2022 | 196 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2022 | 312 | 0.040 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2001 | 270 | 0.040 |
Why?
|
| Taxoids | 1 | 2001 | 126 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2023 | 917 | 0.040 |
Why?
|
| Trastuzumab | 1 | 2020 | 86 | 0.040 |
Why?
|
| Iron | 1 | 2020 | 174 | 0.040 |
Why?
|
| Silicon Dioxide | 1 | 2000 | 39 | 0.040 |
Why?
|
| Antibodies | 1 | 2020 | 348 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2023 | 481 | 0.040 |
Why?
|
| Disease-Free Survival | 3 | 2008 | 1170 | 0.040 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2017 | 107 | 0.030 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2017 | 87 | 0.030 |
Why?
|
| Cell Count | 2 | 2009 | 197 | 0.030 |
Why?
|
| Genomics | 1 | 2023 | 848 | 0.030 |
Why?
|
| Recurrence | 3 | 2008 | 1190 | 0.030 |
Why?
|
| Lymphoma | 1 | 1999 | 247 | 0.030 |
Why?
|
| Chromosome Deletion | 1 | 2017 | 214 | 0.030 |
Why?
|
| Antineoplastic Agents | 2 | 2005 | 2303 | 0.030 |
Why?
|
| Adolescent | 3 | 2025 | 9606 | 0.030 |
Why?
|
| Sample Size | 1 | 2016 | 128 | 0.030 |
Why?
|
| Age Factors | 2 | 2013 | 1906 | 0.030 |
Why?
|
| Hematopoietic Cell Growth Factors | 1 | 1995 | 11 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 876 | 0.030 |
Why?
|
| Carcinoma | 1 | 1998 | 439 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 2016 | 350 | 0.030 |
Why?
|
| Ovarian Neoplasms | 1 | 2001 | 797 | 0.030 |
Why?
|
| Disease Management | 1 | 2016 | 358 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 1995 | 276 | 0.030 |
Why?
|
| Melphalan | 1 | 1994 | 98 | 0.030 |
Why?
|
| Recombinant Proteins | 3 | 2001 | 988 | 0.020 |
Why?
|
| Fatigue | 1 | 2013 | 181 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2016 | 624 | 0.020 |
Why?
|
| Filgrastim | 2 | 2001 | 56 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2010 | 78 | 0.020 |
Why?
|
| Neoplasm Staging | 2 | 2010 | 2017 | 0.020 |
Why?
|
| Immunomodulation | 1 | 2010 | 63 | 0.020 |
Why?
|
| Sex Factors | 1 | 2013 | 1105 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2010 | 244 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2013 | 1161 | 0.020 |
Why?
|
| Calibration | 1 | 2009 | 106 | 0.020 |
Why?
|
| Depression | 1 | 2013 | 544 | 0.020 |
Why?
|
| Mutation | 1 | 2020 | 4272 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2010 | 759 | 0.020 |
Why?
|
| Submitochondrial Particles | 1 | 1987 | 3 | 0.020 |
Why?
|
| Mitochondria, Liver | 1 | 1987 | 29 | 0.020 |
Why?
|
| Neurotoxins | 1 | 1987 | 44 | 0.020 |
Why?
|
| Neutropenia | 2 | 2001 | 209 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2008 | 292 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1994 | 1077 | 0.020 |
Why?
|
| Thromboembolism | 1 | 2008 | 122 | 0.020 |
Why?
|
| Retrospective Studies | 3 | 2009 | 10164 | 0.020 |
Why?
|
| Head and Neck Neoplasms | 1 | 1994 | 1073 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 1987 | 238 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2010 | 636 | 0.020 |
Why?
|
| Neutrophils | 2 | 2000 | 324 | 0.010 |
Why?
|
| Thinness | 1 | 2006 | 45 | 0.010 |
Why?
|
| Siblings | 1 | 2006 | 108 | 0.010 |
Why?
|
| Pyridines | 1 | 1987 | 303 | 0.010 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2006 | 80 | 0.010 |
Why?
|
| Overweight | 1 | 2006 | 120 | 0.010 |
Why?
|
| Immunotherapy | 1 | 2010 | 761 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2006 | 884 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2006 | 476 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 1395 | 0.010 |
Why?
|
| Graft vs Host Disease | 1 | 2006 | 365 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2006 | 1524 | 0.010 |
Why?
|
| Graft Survival | 1 | 2006 | 937 | 0.010 |
Why?
|
| Antineoplastic Protocols | 1 | 2002 | 9 | 0.010 |
Why?
|
| Colloids | 1 | 2000 | 28 | 0.010 |
Why?
|
| Blood Platelets | 1 | 2000 | 150 | 0.010 |
Why?
|
| Stomatitis | 1 | 1998 | 30 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1999 | 242 | 0.010 |
Why?
|
| Esophagitis | 1 | 1998 | 40 | 0.010 |
Why?
|
| Carboplatin | 1 | 2000 | 322 | 0.010 |
Why?
|
| Stem Cells | 1 | 2001 | 387 | 0.010 |
Why?
|
| Pulmonary Alveoli | 1 | 1998 | 72 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 1998 | 401 | 0.010 |
Why?
|
| Vincristine | 1 | 1998 | 99 | 0.010 |
Why?
|
| Mitoxantrone | 1 | 1998 | 65 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2002 | 920 | 0.010 |
Why?
|
| Diarrhea | 1 | 1998 | 179 | 0.010 |
Why?
|
| Methotrexate | 1 | 1998 | 225 | 0.010 |
Why?
|
| Brain Diseases | 1 | 1998 | 172 | 0.010 |
Why?
|
| Doxorubicin | 1 | 1998 | 284 | 0.010 |
Why?
|
| Hemorrhage | 1 | 1998 | 288 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2002 | 1103 | 0.010 |
Why?
|
| Lung Diseases | 1 | 1998 | 283 | 0.010 |
Why?
|
| Cisplatin | 1 | 1998 | 568 | 0.010 |
Why?
|
| Hyperbilirubinemia | 1 | 1995 | 20 | 0.010 |
Why?
|
| Life Tables | 1 | 1995 | 46 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 1999 | 1922 | 0.010 |
Why?
|
| Incidence | 1 | 1998 | 1701 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 1994 | 109 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1994 | 212 | 0.010 |
Why?
|
| Bone Marrow | 1 | 1994 | 409 | 0.010 |
Why?
|
| Cohort Studies | 1 | 1998 | 3054 | 0.010 |
Why?
|
| Time Factors | 1 | 1998 | 5410 | 0.000 |
Why?
|
| 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine | 1 | 1987 | 9 | 0.000 |
Why?
|
| Structure-Activity Relationship | 1 | 1987 | 422 | 0.000 |
Why?
|
| Rats | 1 | 1987 | 4072 | 0.000 |
Why?
|
| Animals | 1 | 1987 | 28155 | 0.000 |
Why?
|